TIDMEMIS
RNS Number : 7998U
EMIS Group PLC
17 July 2018
17 July 2018
EMIS Group plc
("EMIS Group" or "the Group")
Trading update
Notice of half year results
EMIS Group plc (AIM: EMIS.L), the UK leader in connected
healthcare software and services, today announces a trading update
for the six months ended 30 June 2018.
Overview
Trading for the half year has been in line with the Board's
expectations with revenue ahead of the comparative period as the
Group continued to benefit from strong market shares, high levels
of recurring revenue and good visibility in its order books and
pipelines. The Board's expectations for the full year remain
unchanged.
Divisional review
In Primary, Community & Acute Care, the Group's leading
primary care market share has been maintained, while constructive
discussions with NHS Digital continue with progress made in
resolving the service level issues announced in January. The Group
advanced again in Community with further contract wins, and the
Acute business saw an improved performance.
The roll out of ProScript Connect, the Group's next generation
pharmacy dispensary management product in Community Pharmacy, has
continued to plan, with the business moving forward positively.
The improvement in trading in Specialist & Care in the
second half of 2017 was maintained during the period with a strong
focus on operational delivery.
Patient continues to make good progress in building the first UK
marketplace for healthcare. A major step in this project was the
launch of an upgraded Patient Access app in May. In parallel,
patient.info continues to develop its audience with increased focus
on advertising sales.
Financial position
The Group's net cash at 30 June 2018 was GBP32.3m (31 December
2017: GBP14.0m), benefiting from the usual seasonal first half
inflow.
Notice of half year results
The Group intends to announce its results for the half year
ended 30 June 2018 on 31 August 2018.
Andy Thorburn, CEO of EMIS Group, said:
"EMIS Group has continued to trade in line with our
expectations, while at the same time we have delivered good
progress on the key projects set out in March and on developing our
detailed plans for growth. The Board therefore remains confident in
the outlook for the business."
For further information, contact:
EMIS Group plc Tel: 0113 380 3000
Andy Thorburn, CEO
Peter Southby, CFO
www.emisgroupplc.com
Numis Securities Limited (Nominated Adviser & Broker) Tel: 020 7260 1000
Oliver Hardy/Simon Willis/James Black
MHP Communications Tel: 020 3128 8540
Reg Hoare/Giles Robinson/Charlie Barker
Information for investors, including analyst consensus
forecasts, can be found on the Group's website at
www.emisgroupplc.com/investors.
Notes to Editors
EMIS Group is the UK leader in connected healthcare software and
services. Its solutions are widely used across every major UK
healthcare setting from primary, community & acute care, to
high street pharmacies and specialist care services. EMIS Group
helps healthcare professionals in over 10,000 organisations share
vital information, facilitating better, more efficient healthcare
and supporting longer and healthier lives.
EMIS Group serves the following healthcare markets under the
EMIS Health brand:
-- Primary, Community & Acute Care, as the UK leader in
clinical management systems for healthcare providers and
commissioners. EMIS Health products, including the flagship EMIS
Web, hold over 40 million patient records and are used by more than
100,000 professionals in nearly 6,000 healthcare organisations.
-- Community Pharmacy, with the UK's single most used integrated
community pharmacy and retail system.
-- Specialist Care, as England's leading provider of diabetic eye screening software and other ophthalmology-related solutions.
These markets are also supported by other EMIS Group
businesses:
-- under the Patient brand, the UK's leading independent
provider of patient-centric medical and well-being information and
related transactional services.
-- under the Egton brand, providing specialist ICT
infrastructure, hardware and engineering services, and non-clinical
software into health and social care.
-- under the EMIS Care brand, providing healthcare screening
programmes such as diabetic eye screening.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTRFMFTMBMBBMP
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Emis (LSE:EMIS)
Historical Stock Chart
From Apr 2024 to May 2024
Emis (LSE:EMIS)
Historical Stock Chart
From May 2023 to May 2024